Loss of FBXW7 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma

Hepatology Research

Volumn 44, Issue 14, 2014, Pages E346-E352

  Enkhbold, Chinbold ^a   Utsunomiya, Tohru ^a   Morine, Yuji ^a   Imura, Satoru ^a   Ikemoto, Tetsuya ^a   Arakawa, Yusuke ^a   Kanamoto, Mami ^a   Iwahashi, Shuichi ^a   Saito, Yu ^a   Ishikawa, Daichi ^a   Shimada, Mitsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Clinicopathological variables; FBXW7; Intrahepatic cholangiocarcinoma

Indexed keywords

AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FBXW7 GENE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE LOSS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER RESECTION; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84918569355     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12314     Document Type: Article

References (29)

1. Khan SA, Davidson BR, Goldin R etal. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 52: 1-9.
2. Chang KY, Chang JY, Yen Y. Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw 2009; 7: 423-427.
3. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis and treatment. Hepatology 2008; 48: 308-321.
4. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40: 472-477.
5. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10.
6. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 10: 77-82.
7. Yamamoto M, Takasaki K, Yoshikawa T. Extended resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg 1999; 6: 117-121.
8. Ohtsuka M, Ito H, Kimura F etal. Extended hepatic resection and outcomes in intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003; 10: 259-264.
9. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008; 8: 83-93.
10. Spruck CH, Strohmaier H, Sangfelt O etal. hCDC4 gene mutations in endometrial cancer. Cancer Res 2002; 62: 4535-4539.
11. Knuutila S, Aalto Y, Autio K etal. DNA copy number losses in human neoplasms. Am J Pathol 1999; 155: 683-694.
12. Strohmaier H, Spruck CH, Kaiser P, Won K, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and its mutated in a breast cancer cell line. Nature 2001; 413: 316-322.
13. Yada M, Hatakeyama S, Kamura T etal. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004; 23: 2116-2125.
14. Izumi N, Helker C, Ehling M, Behrens A, Herzog W, Adams RH. Fbxw7 controls angiogenesis by regulating endothelial Notch activity. PLos One 2012; 7: e41116.
15. Inuzuka H, Shaik S, Onoyama I etal. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011; 471: 104-109.
16. Mao JH, Kim IJ, Wu D etal. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008; 321: 1499-1502.
17. Tu K, Zheng X, Zan X, Han S, Yao Y, Liu Q. Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. Hepatol Res 2012; 42: 904-910.
18. Ibusuki M, Yamamoto Y, Shinriki S, Ando Y, Iwase H. Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients. Cancer Sci 2011; 102: 439-445.
19. Yokobori T, Mimori K, Iwatsuki M etal. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 2009; 69: 3788-3794.
20. Akhoondi S, Sun D, von der Lehr N etal. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007; 67: 9006-9012.
21. Liver Cancer Study Group of Japan. Classification of Primary Liver Cancer, 1st English edn. Tokyo: Kanehara, 1997.
22. Babaei-Jadidi R, Li N, Saadeddin A etal. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J Exp Med 2011; 208: 295-312.
23. Shwartz AL, Ciechanover A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 2009; 49: 73-96.
24. Choi SB, Kim KS, Choi JY etal. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 2009; 16: 3048-3056.
25. Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Ojima H. Clinical impact of the surgical margin status in hepatectomy for solitary mass-forming type intrahepatic cholangiocarcinoma without lymph node metastasis. J Surg Oncol 2007; 96: 160-165.
26. Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A, Nakayama KI. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 2013; 23: 347-361.
27. Pelengaris S, Khan M. The many faces of c-Myc. Arch Biochem Biophys 2003; 416: 129-136.
28. Kubben FJ, Sier CF, van Duijn W etal. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer 2006; 94: 1035-1040.
29. Calcagno DQ, Freitas VM, Leal MF etal. MYC, FBXW7 and TP 53 copy number variation and expression in Gastric Cancer. BMC Gastroenterol 2013; 13: 141.